Abiomed (ABMD) Tops Q3 EPS by 22c, Offers Q4 Guidance

Abiomed (NASDAQ: ABMD) reported Q3 EPS of $1.35, $0.22 better than the analyst estimate of $1.13. Revenue for the quarter came in at $231.7 million versus the consensus estimate of $225.59 million.

GUIDANCE:

Abiomed sees Q4 2021 revenue of $225-235 million, versus the consensus of $230.96 million.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance
• ATN International (ATNI) Misses Q1 EPS by 46c ; Offers Guidance
• Plexus Corp (PLXS) Tops Q2 EPS by 7c